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Abstract
Background Multifocal visual evoked potential (MF-VEP) assesses a wider visual field than full-field VEP (FF-VEP) and 
potentially offers a more precise analysis of optic nerve injury and repair following optic neuritis. MF-VEP may offer advan-
tages over FF-VEP as an endpoint in clinical trials of remyelinating therapies.
Objective MF-VEP testing was used to study changes in visual pathways in 48% of RENEW [phase II, opicinumab (anti-
LINGO-1; BIIB033) vs. placebo after first acute unilateral optic neuritis] participants.
Methods This exploratory MF-VEP RENEW substudy compared mean outcomes at weeks 24 and 32 among participants 
in the intent-to-treat (ITT; n = 39; 72% female; mean age: 32.3 years) and per-protocol (PP; n = 31; 71% female; mean age: 
32.2 years) populations in affected and fellow eye latency from fellow eye baseline latency and affected and fellow eye ampli-
tude from their own baselines. Treatment differences were evaluated using analysis of covariance (week 24) and a mixed-
effect model of repeated measures (week 32). Last observation carried forward was used to impute missing data at week 24.
Results A trend for improvement in affected eye MF-VEP latency with opicinumab versus placebo was seen in the ITT and 
PP populations at weeks 24 and 32. Both treatment groups in the ITT population experienced partial recovery of amplitude 
in the affected eye at week 32. Notably, the mean change in fellow eye amplitude at weeks 24 and 32 was − 17.57 and − 31.41 
nanovolts (nV) in placebo but only − 0.59 and 1.93 nV in the opicinumab group [differences at weeks 24 and 32: 16.98 nV 
(p = 0.050) and 33.33 nV (p < 0.01), respectively].
Conclusion Results from this substudy showed advantages of MF-VEP over FF-VEP in multicenter studies of central nerv-
ous system reparative therapies and provide novel evidence that fellow eye visual pathway amplitude loss occurs after optic 
neuritis but can potentially be prevented by opicinumab treatment.
Registration ClinicalTrials.gov identifier NCT01721161.
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Key Points 
The RENEW primary study (NCT01721161), which 
assessed the efficacy and safety of opicinumab (anti-
LINGO-1; BIIB033) in participants after a first episode 
of acute optic neuritis (AON), included a substudy to 
measure changes in latency and amplitude in both the 
affected and fellow eyes using multifocal visual evoked 
potential (MF-VEP).
Latency changes measured by MF-VEP were highly 
correlated with full-field VEP (FF-VEP) latency changes 
measured both within this substudy and in the primary 
RENEW study, confirming the treatment effect demon-
strated by opicinumab in the RENEW study.
MF-VEP appears superior to FF-VEP by showing similar 
treatment effects on latency delay with a smaller sample 
size and revealing treatment effects on amplitude that 
were not apparent with FF-VEP.
Treatment with opicinumab prevented the progressive 
fellow eye visual pathway amplitude loss following AON 
that was demonstrated by the placebo group and also 
reduced amplitude loss in the affected eye following 
AON.
1 Introduction
Opicinumab (anti-LINGO-1; BIIB033) is a fully human 
monoclonal antibody against LINGO-1 [1]. Following 
testing in preclinical models and phase I studies [1, 2], a 
phase II clinical development program was initiated to inves-
tigate opicinumab as a potential treatment for central nerv-
ous system (CNS) demyelinating disorders.
RENEW was the first multicenter randomized clinical 
trial to investigate a potential CNS remyelinating therapy in 
humans. Opicinumab was compared with placebo (in addi-
tion to standard intravenous [IV] corticosteroid pulse ther-
apy) in participants with a first episode of acute optic neuri-
tis (AON), with treatment starting 3–4 weeks after the first 
symptom and continuing for up to 8 months. A first AON 
episode was selected because it is often the first manifesta-
tion of multiple sclerosis (MS) and allows the study of two 
potential mechanisms for LINGO-1 blockade: remyelination 
[via improved latency of the visual evoked potential (VEP)], 
and neuroprotection [via preservation of retinal nerve fiber 
layer thickness measured by spectral domain optical coher-
ence tomography (SD-OCT) and VEP amplitude]. RENEW 
primary endpoint analysis demonstrated some improvement 
in full-field (FF)-VEP latency recovery in the affected eye 
relative to the unaffected eye at baseline, consistent with 
enhanced remyelination of the recently affected optic nerve 
[3].
FF-VEP is a sensitive and objective tool for detecting 
latency abnormalities in the visual pathway [4] and repre-
sents combined activity of the central part of the visual field. 
In contrast, multifocal (MF)-VEP is performed by simultane-
ously stimulating multiple individual regions of the visual 
field using different pseudorandom sequences for different 
segments. By cross-correlating each sequence with the raw 
electroencephalogram signal, responses to unique sequences 
corresponding to each of the individually stimulated seg-
ments are extracted. Thus, a wider and more detailed assess-
ment of the visual field is performed using MF-VEP, allow-
ing better identification of regional changes in amplitude and 
latency and potentially a more precise analysis of injury and 
repair following AON [5–8]. Furthermore, since the VEP 
signal is generated by dipoles oriented perpendicularly to 
the brain surface, the upper and lower calcarine visual cor-
tex produces mostly opposing waveforms and, as a result, 
FF-VEP but not MF-VEP is prone to cancellation [9]. Indi-
vidual MF-VEP waveforms are generated independently by 
small areas of the visual cortex and are not affected by signal 
cancellation between the upper and lower fields. MF-VEP 
reproducibility over time is excellent [10, 11], as is its sensi-
tivity to detect changes [12]. A technical feasibility study of 
MF-VEP latency demonstrated a variability (over two tests) 
within 2 ms for healthy controls and individuals with pre-
existing optic neuritis and a strong correlation between the 
first and second tests (r = 0.9997) [13].
Prolonged latencies and decreased or absent cortical MF-
VEP amplitudes with monocular stimulation are hallmarks 
of AON [6, 14, 15] and are caused by inflammatory demy-
elination and conduction block and/or axonal injury. Signifi-
cant amplitude recovery and some latency recovery typically 
occur spontaneously via resolution of inflammation, ion 
channel redistribution in demyelinated axons, and remyeli-
nation [16]. In RENEW, we included an MF-VEP substudy 
in 48% of participants to measure changes in latency and 
amplitude in the affected and fellow eye visual pathways in 
greater detail. This is the first time MF-VEP has been used 
in a multicenter therapeutic clinical trial.
2  Methods
2.1  RENEW Study Design
The design and methodology of RENEW (NCT01721161) 
have been described previously [3]. Briefly, participants 
aged 18–55 years experiencing a first unilateral AON epi-
sode and with no history of MS were randomized 1:1 to 
placebo or opicinumab 100 mg/kg IV every 4 weeks from 
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baseline to week 20 (six treatments) with follow-up until 
week 32. Patients with fellow eye VEP latency abnormali-
ties were excluded from RENEW [3]. Prior to randomiza-
tion, all participants were treated within 28 days of the first 
AON symptom onset with high-dose IV corticosteroids. An 
opicinumab 100 mg/kg dose was selected for this proof-
of-biology study because it was the highest dose tested in 
phase I trials, was found to be safe and well-tolerated, and 
is predicted to result in CNS exposures above the 90% effec-
tive concentration for remyelination in rodent pharmacol-
ogy models [2]. All participants provided written informed 
consent, the study was performed in accordance with the 
International Conference on Harmonisation Good Clinical 
Practice guidelines and the Declaration of Helsinki [17, 18], 
and all investigators obtained approval from their local eth-
ics committees.
2.2  Multifocal Visual Evoked Potential (MF‑VEP) 
Methodology
As specialist equipment was provided to the sites that 
participated in the MF-VEP substudy, it was not possible 
to perform MF-VEP at all locations. Thirteen of the sites 
participating in RENEW were selected for the MF-VEP 
substudy and supplied with MF-VEP machines (Vision-
Search 1 system; VisionSearch, Sydney, NSW, Australia) 
by the sponsor (Biogen). Technicians at all 13 sites were 
trained in person and were qualified to perform MF-VEP 
by one of the authors (AK), followed by formal assessment 
by the central reader (Duke University Clinical Research 
Center, Durham, NC, USA). MF-VEP measurements were 
taken at screening, baseline, weeks 4, 8, 12, 16, 20, and 24 
(± 3 days), and at week 32 (± 7 days). For participants who 
discontinued study treatment early or withdrew prematurely 
from the study, MF-VEP was measured at the early termina-
tion visit that was completed 4 weeks (± 7 days) after their 
last study treatment. The individual segments assessed by 
MF-VEP are shown in Fig. 1a.
Fifty-six cortically scaled segments containing a 4 × 4 
grid of black-and-white checks reversing according to 
pseudorandom sequences were used for monocular visual 
field stimulation (Fig. 1b). The visual stimulus was gen-
erated on a 21-inch high-resolution liquid crystal display 
screen and occupied 48° of the visual field. All participants 
were optimally refracted for near vision and the pupils were 
not dilated. They were seated 30 cm from the screen. Four 
gold-cup electrodes (Grass Technologies, West Warwick, 
RI, USA) were used for bipolar recording: two electrodes 
positioned 4 cm on either side of the inion, one electrode 
in the midline 2.5 cm above the inion, and one electrode 
4.5 cm below the inion. Conductive gel was injected under 
each electrode (0.5 mL). Electrical signals were recorded 
along two channels: vertical (using superior and inferior 
electrodes) and horizontal (using left and right electrodes). 
A ground electrode was placed on an ear lobe. Each of the 
56 segments was stimulated with a different frequency and 
the resultant VEP responses were amplified 100,000 times 
and band-pass filtered (1–20 Hz). For amplitude analysis, 
the largest (between two channels) peak–trough amplitude 
within the interval of 70–200 ms was determined. The sec-
ond peak of the maximum amplitude wave for each visual 
field segment was used for latency analysis. The software 
of the MF-VEP equipment calculated the average amplitude 
and frequency from the individual segments. If a segment 
had no detectable amplitude, then a reading of 0 nanovo-
lts (nV) was assigned. Latency measurements were only 
assigned to segments with amplitude readings not equal to 
0 nV. Segments with undetectable amplitude readings did 
not have a latency assigned. No compensation for peripheral 
sectors and no imputations were performed.
The blinded central reader was responsible for MF-VEP 
data quality control and for latency and amplitude meas-
urement at the individual subject level using progression 
Fig. 1  Individual segments assessed using a multifocal visual evoked 
potential and b reversing black-and-white checks used for monocular 
stimulation
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analysis for each of the 56 segments from all available study 
visits.
2.3  Full‑Field Visual Evoked Potential (FF‑VEP) 
and Spectral Domain Optical Coherence 
Tomography (SD‑OCT) Methodology
FF-VEP latency and amplitude as well as retinal ganglion 
cell layer/inner plexiform layer (RGCL/IPL) thickness, 
measured by SD-OCT, were assessed in the main RENEW 
study. Both methods used a standard protocol provided by 
the central reading center to ensure reproducibility and 
consistency, as described previously [3]. The FF-VEP pro-
tocol was developed to comply with guidelines from both 
the International Society for Clinical Electrophysiology of 
Vision and the American Clinical Neurophysiology Soci-
ety. SD-OCT scan images were obtained using a  Spectralis® 
(Heidelberg Engineering, Heidelberg, Germany) or Cirrus™ 
(Carl Zeiss Meditec, Dublin, CA, USA) system. Central 
reading, certification, and quality control procedures, as well 
as the optical coherence tomography (OCT)-scanning pro-
tocol, complied with the APOSTEL (Advised Protocol for 
OCT Study Terminology and Elements) recommendations 
[3, 19]. The central reader evaluated all data and provided 
the final values and interpretations. FF-VEP and RGCL/IPL 
data for substudy participants were obtained from the main 
study results.
2.4  Statistical Analyses
In this substudy, the primary efficacy analysis was change 
in MF-VEP-affected eye latency at week 24 (end of treat-
ment) from baseline of the unaffected (fellow) eye in mil-
liseconds. A key hurdle when measuring changes from 
baseline in AON VEP latency is that pretreatment latency 
delay from demyelination cannot be determined because of 
the high prevalence of conduction block and residual acute 
inflammation in the affected eye optic nerve. To overcome 
this limitation, RENEW required each participant to have a 
normal fellow (unaffected) eye to acquire the normal, pre-
AON onset latency values.
In addition to latency, exploratory efficacy analyses were 
included to measure changes from baseline in affected and 
fellow eye MF-VEP amplitude over time expressed in nano-
volts. Segments without recordable affected eye amplitude 
were scored as 0 nV. To visualize changes in amplitude from 
baseline in all 56 MF-VEP segments in the affected and fel-
low eyes, heat map displays were generated for each visit 
(R statistical software), with green representing amplitude 
gains (improvements) from baseline and red representing 
amplitude losses (worsening) from the baseline value of the 
respective eye.
All participants in the MF-VEP substudy were included 
in the intent-to-treat (ITT) population and received at least 
one dose of study drug or placebo. MF-VEP substudy par-
ticipants who were included in the per-protocol (PP) popu-
lation in the full trial (defined as those who completed the 
study, did not miss more than one treatment dose, and did 
not receive MS disease-modifying therapy) formed the PP 
population in the MF-VEP substudy. The PP population 
analysis was post hoc in the MF-VEP substudy.
Demographic data were summarized using descriptive 
statistics. Values for affected and unaffected fellow eye MF-
VEP latency and amplitude at each visit were summarized 
using descriptive statistics by treatment group. Treatment 
differences in MF-VEP latency and amplitude were evalu-
ated using analysis of covariance (ANCOVA) at week 24 
and a mixed-effect model of repeated measures (MMRM) 
through week 32. Last observation carried forward was used 
to impute missing data at week 24 in the ANCOVA evalu-
ation. ANCOVA and MMRM models were adjusted for the 
baseline value of the outcome being examined.
Participants with FF-VEP latency recovery at week 24 
were prespecified as those with an affected eye FF-VEP 
latency ≤ 10% worse than the fellow eye. Mean differences 
in MF-VEP latency and amplitude at week 24 in participants 
with and without FF-VEP latency recovery from baseline 
impairment were evaluated by ANCOVA. Correlations 
of MF-VEP with FF-VEP and RGCL/IPL thickness were 
assessed using pairwise correlation and the Pearson correla-
tion coefficient.
The MF-VEP substudy was not designed to reach signifi-
cance for testing treatment effect on latency or amplitude. p 
values reported were not adjusted for multiple testing. The 
magnitude of the treatment effect was unknown at the time 
the substudy was designed because RENEW was the first 
time the efficacy of opicinumab for CNS remyelination was 
examined in the clinic. Data were checked for normality and 
were found to be normally distributed.
3  Results
3.1  Enrollment in the MF‑VEP Substudy 
and Baseline Characteristics
Thirty-nine (48%) participants in the RENEW ITT popu-
lation were included in the MF-VEP substudy, mandatory 
at all 13 sites selected for substudy participation. Of the 
39 participants, 21 were randomized to opicinumab and 
18 to placebo. The two treatment groups were similar in 
baseline demographics except for conduction block in the 
affected eye, which was more frequent in the opicinumab 
group (Table 1). Fellow eye MF-VEP latency and ampli-
tude values were normal at baseline; average latency for a 
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control cohort was previously reported as 145.9 ± 4.6 ms and 
149.3 ± 5.1 ms [13, 20] for both sides and the normal aver-
age range for amplitude was reported as 156–210 nV [21]. 
The mean affected eye baseline amplitude was reduced by 
approximately half in both treatment groups compared with 
the fellow eye (Table 1).
Thirty-one (45%) of 69 participants in the main study PP 
population were represented in the MF-VEP substudy PP 
population, with 15 randomized to opicinumab and 16 to 
placebo (Table 2). The substudy population was representa-
tive of the overall participant population in RENEW.
3.2  Recovery of MF‑VEP Latency in the Affected Eye
Both groups showed MF-VEP latency prolongation at the 
end of treatment (week 24) and end of study (week 32). In 
the ITT population, the adjusted mean change in latency 
in the opicinumab group compared with placebo at week 
24 was − 4.97 ms [95% confidence interval (CI) − 16.03 to 
6.09; p = 0.37]; in the PP population, it was − 11.78 ms (95% 
CI − 24.28 to 0.73; p = 0.06; by ANCOVA; Fig. 2). The cor-
responding data at Week 32 were − 3.82 ms (95% CI − 15.10 
to 7.46; p = 0.50) and − 9.38 ms (95% CI − 22.22 to 3.46; 
p = 0.15; by MMRM; Fig. 2). Although the average improve-
ment in MF-VEP latency was numerically almost twofold 
higher with opicinumab than with placebo at both timepoints 
in the PP population, the data were highly variable and the 
Table 1  Baseline demographic characteristics of all participants in the MF-VEP substudy
MF-VEP multifocal visual evoked potential, nV nanovolts, SD standard deviation
a n = 20; baseline height and MF-VEP latency and amplitude not available for one participant
b n = 38; baseline height and MF-VEP latency and amplitude not available for one participant
c Participants with recordable latency in < 60% of segments at baseline were considered to have conduction block at baseline
Characteristic Placebo (n = 18) Opicinumab (n = 21) All participants (N = 39)
Female (%) 78 67 72
White (%) 94 100 97
Mean ± SD age (years) 31.8 ± 9.93 32.7 ± 7.90 32.3 ± 8.78
Weight (kg) [median (range)] 75.0 (47–119) 72.2 (57–106) 75.0 (47–119)
Height (cm) [median (range)] 170.0 (155–194) 171.0 (158–185)a 170.0 (155–194)b
Mean ± SD MF-VEP latency of the fellow eye (ms) 144.45 ± 6.22 147.68 ± 5.33a 146.15 ± 5.92b
Mean ± SD MF-VEP latency of the affected eye (ms) 167.61 ± 19.90 166.65 ± 19.69a 167.10 ± 19.53b
Mean ± SD MF-VEP amplitude of the fellow eye (nV) 156.77 ± 57.30 167.36 ± 34.60a 162.34 ± 46.39b
Mean ± SD MF-VEP amplitude of the affected eye (nV) 87.21 ± 48.57 78.36 ± 57.63a 82.56 ± 53.01b
No. (%) with < 60% measurable  segmentsc 4 (22) 9 (45)a 13 (34)b
Table 2  Baseline demographic characteristics of participants in the MF-VEP substudy per-protocol population
MF-VEP multifocal visual evoked potential, nV nanovolts, SD standard deviation
a n = 14; baseline height and MF-VEP latency and amplitude not available for one participant
b n = 30; baseline height and MF-VEP latency and amplitude not available for one participant
c Participants with recordable latency in < 60% of segments at baseline were considered to have conduction block at baseline
Characteristic Placebo (n = 16) Opicinumab (n = 15) All participants (N = 31)
Female (%) 75 67 71
White (%) 94 100 97
Mean ± SD age (years) 32.8 ± 10.14 31.7 ± 7.83 32.2 ± 8.97
Weight (kg) [median (range)] 75.0 (51–119) 75.0 (57–106) 75.0 (51–119)
Height (cm) [median (range)] 170.0 (157–194) 172.5 (159–182)a 170.5 (157–194)b
Mean ± SD MF-VEP latency of the fellow eye (ms) 143.67 ± 6.01 147.66 ± 4.98a 145.53 ± 5.82b
Mean ± SD MF-VEP latency of the affected eye (ms) 169.80 ± 19.80 162.87 ± 18.37a 166.56 ± 19.14b
Mean ± SD MF-VEP amplitude of the fellow eye (nV) 159.23 ± 56.30 163.54 ± 38.40a 161.24 ± 48.01b
Mean ± SD MF-VEP amplitude of the affected eye (nV) 83.27 ± 48.04 82.93 ± 56.13a 83.11 ± 51.05b
No. (%) with < 60% measurable  segmentsc 4 (25) 6 (43)a 10 (33)b
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study was therefore underpowered to detect a statistically 
significant treatment effect.
A post hoc comparison of estimated effect size for change 
in MF-VEP and FF-VEP latency for opicinumab versus pla-
cebo at week 24 in the ITT population showed that MF-VEP 
demonstrated a larger treatment effect size than FF-VEP 
(Table 3).
3.3  Recovery of MF‑VEP Amplitude in the Affected 
Eye
Both treatment groups experienced amplitude recovery 
in the affected eye from baseline; there was no significant 
between-group difference in recovery at week 24. However, 
there was a strong trend for improvement with opicinumab 
over 32 weeks; the mean gain versus placebo was 22.32 nV 
(95% CI − 1.26 to 45.89; p = 0.06; Fig. 3a; MMRM; ITT 
population). The recovery in the placebo group peaked by 
week 16 and appeared to worsen towards the end of the 
study, whereas the opicinumab group continued to improve 
through the last study assessment (week 32). The heat map 
display revealed that the greatest recovery occurred in the 
segments with recording electrodes closest to the visual 
cortical area generating the signal (i.e., the upper calcarine 
visual cortex; Fig. 3a), a consequence of the anatomy of the 
visual cortex [9, 22].
3.4  MF‑VEP Latency and Amplitude in the Fellow 
Eye
No change from baseline in fellow eye visual path-
way latency was observed in either treatment group over 
32 weeks; in the ITT population, the adjusted mean change 
from baseline at week 24 by MMRM was 0.61 ms for opici-
numab and 2.26 ms for placebo (p = 0.15). The correspond-
ing values at week 32 were 1.92 ms for placebo and 1.32 ms 
for opicinumab (p = 0.52).
By contrast, there was a significant, gradual loss of MF-
VEP amplitude in the placebo group that was not seen in the 
opicinumab group; in the ITT population at week 24, the 
adjusted mean change in the fellow eye MF-VEP amplitude 
by MMRM was − 17.57 nV in the placebo group but only 
− 0.59 nV in the opicinumab group [difference in adjusted 
mean change: 16.98 nV (95% CI − 0.23 to 34.18); p = 0.05]. 
The corresponding values at week 32 were − 31.41 and 
1.93 nV in the placebo and opicinumab groups, respectively 
(p < 0.01; Fig. 3b). The heat map display of the individual 
segments showed that the progressive fellow eye visual path-
way amplitude loss involved the majority of segments and 
was greatest in the segments corresponding to the visual 
cortical neurons closer to the MF-VEP scalp electrodes, 
similar to the findings in the affected eye visual pathway. 
In the opicinumab group, only a few segments experienced 
transient and mild loss of amplitude.
3.5  Correlations of MF‑VEP with FF‑VEP and SD‑OCT
A prespecified responder analysis of the RENEW primary 
endpoint classified responders as those whose affected eye 
latency at week 24 was within 10% of the fellow eye latency 
at baseline [3]. We investigated the relationship between this 
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Fig. 2  Mean change in MF-VEP latency, adjusted for the baseline 
latency of unaffected fellow eye, at a week 24 and b week 32 in the 
affected eye compared with the unaffected fellow eye at baseline in 
the substudy ITT and PP populations. Error bars represent 95% CIs. 
aAnalyzed by analysis of covariance. bAnalyzed by mixed-effect 
model of repeated measures. CI confidence interval, ITT intent-to-
treat, MF-VEP multifocal visual evoked potential, PP per protocol
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responder analysis and the changes observed in latency and 
amplitude by MF-VEP. The results showed that MF-VEP 
latency recovery at week 24 was significantly greater in par-
ticipants who were FF-VEP latency responders at week 24 
(p < 0.01; Fig. 4). MF-VEP amplitude loss also appeared to 
be lower in FF-VEP latency responders at week 24 (p = 0.10; 
Fig. 4). In fact, in the affected eye visual pathway, changes 
in MF-VEP latency at week 24 showed a high correlation 
with changes in FF-VEP latency in both treatment groups 
(Table 4). By contrast, the correlation was weaker between 
MF-VEP and FF-VEP in amplitude changes over 24 weeks 
and between MF-VEP latency and amplitude with RGCL/
IPL as measured by SD-OCT. OCT was used as a secondary 
endpoint in RENEW to investigate the potential for opici-
numab to provide neuroprotection of RGC following AON 
(Table 4).
4  Discussion
This is the first time MF-VEP has been used in a multi-
center therapeutic clinical trial. Results from this explora-
tory MF-VEP substudy of RENEW showed the feasibility 
of performing MF-VEP in multicenter studies of candidate 
CNS reparative therapies. Owing to its low sample size, this 
exploratory MF-VEP substudy was not designed for statisti-
cal significance, but to provide valuable information on the 
latency and amplitude changes of both the affected and fel-
low eyes following AON and the potential treatment effects 
of opicinumab for both remyelination and neuroprotection 
in the visual pathway. Importantly, the changes in affected 
eye latency from baseline of the fellow eye were consistent 
between the MF-VEP substudy and FF-VEP, the primary 
endpoint in RENEW [3]. There was also very high concord-
ance in the measurements of affected eye visual pathway 
latency delay following AON between FF-VEP (measured 
manually on the first wave by a central reader) and MF-
VEP (measured automatically on the second wave using 
a machine algorithm) in both the placebo and opicinumab 
groups (Table 4). The assessment of treatment effect statisti-
cal significance was similar, even though the MF-VEP sub-
study involved half the number of participants as RENEW.
MF-VEP was hypothesized to be superior to FF-VEP for 
several reasons, including the ability to detect small outer 
field defects not detected by FF-VEP, higher sensitivity 
to assess severely reduced activity, and higher reliability 
for latency, and especially for amplitude in longitudinal 
measurements [13]. Predictably, the MF-VEP latency data 
generated were consistent with the FF-VEP latency results 
from the overall study (Table 5). Furthermore, participants 
whose FF-VEP latency recovered to normal/close to nor-
mal in RENEW (FF-VEP latency responders; Table 5) 
showed significantly less prolongation in MF-VEP latency 
and lower MF-VEP amplitude loss from baseline to week 
24 than participants without FF-VEP latency recovery. 
This confirms the treatment effect observed with FF-VEP 
in RENEW using separate measurements of latency recov-
ery and highlights the potential of MF-VEP to provide 
similar information with a smaller sample size in thera-
peutic trials (39 participants in the MF-VEP substudy vs. 
82 participants in RENEW yielded similar statistical dif-
ferences by treatment; Table 5) [3]. A post hoc analysis 
of treatment effect size for opicinumab over placebo on 
latency delay showed that MF-VEP had a larger effect size 
than FF-VEP, indicating that a potentially smaller sample 
size is needed with MF-VEP to achieve the same power 
needed with FF-VEP. While the current study was under-
powered to detect a treatment effect, these results suggest 
that MF-VEP could be a preferred endpoint to FF-VEP 
in future optic neuritis trials because it could potentially 
demonstrate similar treatment effects with about half the 
sample size, in addition to detecting treatment effects on 
amplitude that are not measurable with FF-VEP.
A novel finding from this exploratory MF-VEP study 
was that fellow eye visual pathway amplitude loss occurred 
following unilateral optic neuritis in the opposite eye. 
Furthermore, this did not occur in the opicinumab group. 
Table 3  Comparison of multifocal visual evoked potential and full-field visual evoked potential effect sizes in the intent-to-treat population of 
RENEW at week 24
FF-VEP full-field visual evoked potential, MF-VEP multifocal visual evoked potential, SD standard deviation
a Absolute values are shown
b Estimated with Cohen’s d, assuming equal variance
Outcome Estimate (difference in adjusted mean estimated 
from model)a
SD of change at Week 24 in 
placebo
Effect size 
(estimate/
SD)a,b
Change in MF-VEP latency at week 24 
for opicinumab vs. placebo
4.97 16.729 0.297
Change in FF-VEP latency at week 24 
for opicinumab vs. placebo [3]
3.48 15.898 0.219
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Fig. 3  Mean change in multifocal visual evoked potential amplitude 
by treatment from baseline over 32 weeks in the a affected eye and b 
unaffected fellow eye in the intent-to-treat population. In the heat map 
displays, green represents amplitude gains (improvement) and red 
represents amplitude losses (worsening) from baseline. Results for the 
per protocol population were not calculated. aCompared with baseline 
value of the affected eye. bCompared with baseline value of the fellow 
eye. CI confidence interval, nV nanovolts
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Replication and mechanistic investigations to substantiate 
these novel findings will be important.
There are several potential explanations for the observed 
fellow eye visual pathway amplitude loss in the placebo 
arm. First, it may be due to inflammation in the affected 
eye also affecting the optic chiasm and fellow eye, with 
edema causing transient conduction block, which could 
reduce the amplitude. However, the MF-VEP amplitude 
loss was not temporarily linked to AON onset but, instead, 
gradually worsened over time following AON and peaked at 
32 weeks. This is the opposite of what would be expected if 
acute inflammation related to the affected eye AON lesion 
was the cause.
Second, it may be due to new lesions developing in the 
fellow eye visual pathway, possibly occurring in the optic 
nerve, tract or radiation, and/or visual cortex, causing axonal 
transection and/or axonal demyelination and reduced ampli-
tude. However, the magnetic resonance imaging (MRI) scans 
at 32 weeks showed very few new cerebral lesions, and the 
effect would have had to occur in almost all participants in 
the MF-VEP substudy. As described in previous studies, the 
T2 sequences used in the RENEW study were appropriate 
to detect the onset of new lesions in the brain, including the 
optic radiations [23]. Also, little increase in brain T2 lesion 
volume was seen in RENEW between baseline and week 32, 
with no difference between treatment groups, suggesting that 
new lesion development is an unlikely reason for the new 
onset of MF-VEP fellow eye visual pathway amplitude loss 
[3]. A location for these potential new lesions in the optic 
tract is also possible but unlikely, as optic tract lesions occur 
infrequently in MS [24–26]. Visual cortex lesions are also 
possible, but they tend to occur in later phases of MS rather 
than in this early population [6, 27] and are unlikely to be 
so widespread as to involve the majority of visual fields in 
most individuals (Fig. 3). If they did occur, these cortical 
lesions would not be visible by conventional MRI. Finally, 
a therapeutic effect on new lesion development produced by 
opicinumab is unlikely, as this antibody had no such effect in 
animal studies [28, 29] or in phase 1 or the RENEW studies.
Third, the amplitude loss could have resulted from anter-
ograde transsynaptic visual cortex degeneration following 
AON, which is expected to also affect secondary axons com-
ing from the fellow eye visual pathway. MRI studies in vari-
ous eye diseases have shown secondary structural changes 
in the visual cortex following unilateral injury to the retina. 
In the case of anterograde transsynaptic degeneration, it 
has been hypothesized that axonal breakdown at the site of 
injury on one side spreads to connected neurons from the 
contralateral side at the occipital cortex level [30]. There is 
some evidence of both anterograde and retrograde transsyn-
aptic degeneration in MS. In particular, anterograde trans-
synaptic degeneration has been observed following optic 
neuritis and resulted in localized cortical atrophy [31]. Ret-
rograde transsynaptic degeneration, where damage spreads 
from the visual cortex proximally toward the eye, has also 
been suggested as a mechanism of axonal damage in MS. 
Thus, transsynaptic visual pathway degeneration could cause 
secondary visual pathway dysfunction and may represent a 
novel therapeutic target to protect the overall integrity of the 
visual network following unilateral visual pathway lesions, 
such as in AON [28]. Since LINGO-1 blockade is known to 
have both remyelinating and neuroaxonal protective effects 
in various preclinical models [1, 28, 32–36], it is possible 
that the observed preservation of MF-VEP amplitude in the 
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Fig. 4  Adjusted mean differences in a MF-VEP latency and b ampli-
tude at week 24 in participants classified with latency recovery using 
the primary endpoint measure of FF-VEP. FF-VEP latency recovery 
was defined as affected eye FF-VEP latency at week 24 ≤ 10% worse 
than the baseline fellow eye; FF-VEP latency was the primary end-
point in RENEW. CI confidence interval, FF-VEP full-field visual 
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fellow eye visual pathway following AON treatment with 
opicinumab represents a protective therapeutic effect from 
transsynaptic degeneration after AON.
Fourth, it is also possible that the fellow eye amplitude 
loss represents compensatory functional changes in the vis-
ual cortex to adapt to loss of vision in the affected eye result-
ing from AON. Importantly, the reduced rate of amplitude 
recovery in the affected eyes and new onset of amplitude 
loss in the fellow eye in the placebo arm occurred within a 
similar timeframe, which suggests that the two may be func-
tionally related. These adaptive changes may have been pre-
vented by treatment with opicinumab. The human visual cor-
tex is known to display significant degrees of neuroplasticity 
[37] that may enable a degree of functional reorganization 
to compensate for loss of unilateral visual input and, for the 
brain, a chance to optimize cerebral binocular vision even 
at the cost of lowering overall amplitude [37–41]. There is 
some emerging evidence that LINGO-1 signaling pathways 
are involved in neuroplasticity. One study showed LINGO-1 
antagonism increased long-term potentiation (LTP) and 
prevented the decrease of LTP induced by Nogo-P4; these 
effects were mediated via Nogo-66 and the ROCK2–Cofilin 
pathway, which under normal conditions restricts LTP by 
preventing actin polymerization and maintaining synaptic 
stability [42]. Furthermore, blocking Nogo-A increased den-
dritic spine numbers and length in CA3 pyramidal neurons, 
while a significant increase in miniature excitatory post-
synaptic current amplitude was observed at hippocampal 
synaptic sites shortly after administration of an anti-Nogo-
A antibody, along with an increase in α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid receptor density that is 
crucial for plasticity [43]. LINGO-1 has been found to be 
expressed at distal axonal-synaptic structures [44]. These 
observations raise the intriguing possibility that opicinumab 
via LINGO-1 blockade may modulate signaling pathways 
involved in neuroplasticity.
Limitations of this study include the small sample size. 
Additionally, as previously reported by Cadavid et al. [3], 
initiation of opicinumab treatment in RENEW occurred after 
the majority of retinal thinning had taken place, which lim-
ited the therapeutic window for potential treatment benefit 
on RGC and optic nerve neuroprotection from opicinumab.
Table 4  Correlations of the change at week 24 comparing multifocal visual evoked potential, full-field visual evoked potential, and spectral 
domain optical coherence tomography by treatment group
Pearson correlation analyses were used. All correlation analyses for the affected eye were assessed using baseline of the fellow eye
FF-VEP full-field visual evoked potential, ITT intent to treat, MF-VEP multifocal visual evoked potential, PP per protocol, RGCL/IPL retinal 
ganglion cell layer/inner plexiform layer
Substudy and ITT (r) Substudy and PP (r)
Placebo (n = 18) Opici-
numab 
(n = 21)
Total (N = 39) Placebo (n = 16) Opici-
numab 
(n = 15)
Total (N = 31)
MF-VEP latency and FF-VEP latency 0.98 0.91 0.95 0.98 0.93 0.96
MF-VEP amplitude and FF-VEP amplitude 0.63 − 0.24 0.05 0.63 − 0.12 0.15
MF-VEP latency and MF-VEP amplitude − 0.54 − 0.31 − 0.43 − 0.54 − 0.30 − 0.45
MF-VEP amplitude and FF-VEP latency − 0.42 − 0.58 − 0.48 − 0.42 − 0.52 − 0.45
MF-VEP latency and RGCL/IPL thickness − 0.35 − 0.50 − 0.37 − 0.35 − 0.50 − 0.37
MF-VEP amplitude and RGCL/IPL thickness 0.28 0.51 0.39 0.28 0.51 0.38
Table 5  Multifocal visual evoked potential substudy and RENEW study outcomes
FF-VEP full-field visual evoked potential, ITT intent to treat, MF-VEP multifocal visual evoked potential, PP per protocol
Study/outcomes ITT PP
MF-VEP substudy
 Change in MF-VEP latency at week 24 for opicinumab vs. placebo − 4.97 ms (p = 0.37) − 11.78 ms (p = 0.06)
 Change in MF-VEP latency at week 32 for opicinumab vs. placebo − 3.82 ms (p = 0.50) − 9.38 ms (p = 0.15)
RENEW study (Cadavid et al. [3])
 Change in FF-VEP latency at week 24 for opicinumab vs. placebo − 3.48 ms (p = 0.33) − 7.55 ms (p = 0.05)
 Change in FF-VEP latency at week 32 for opicinumab vs. placebo − 6.06 ms (p = 0.07) − 9.13 ms (p = 0.01)
 Participants with latency recovery at week 24; opicinumab/placebo (%) 53/26 54/27
1169Opicinumab Efficacy in AON Using MF-VEP
5  Conclusion
By generating reliable and informative results in a multi-
center international substudy, the feasibility of using MF-
VEP as a proof-of-concept biomarker for candidate CNS 
neuroreparative treatment studies in the AON setting has 
been established. Furthermore, several important observa-
tions were made. First, MF-VEP latency changes were highly 
correlated (r ≥ 0.91) with FF-VEP latency changes, corrobo-
rating the primary endpoint results in RENEW regarding 
improvement of VEP latency following AON treatment with 
opicinumab. Second, the novel finding of progressive fel-
low eye visual pathway amplitude loss following AON was 
identified. Third, opicinumab treatment prevented the fellow 
eye amplitude loss observed following AON and reduced it 
in the affected eye. If the amplitude loss is due to antero-
grade transsynaptic degeneration in the visual cortex, this 
finding raises the possibility that LINGO-1 blockade with 
opicinumab could function as a neuroprotective therapy for 
the visual system. If the amplitude loss in the placebo arm 
is due to plasticity, this indicates that LINGO-1 blockade 
with opicinumab could be used to modulate neuroplasticity 
postsynaptically. Both possibilities require further investiga-
tion in clinical and experimental settings.
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